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Abstract
Background: A surgical resection is currently the preferred treatment for esophageal cancer if
the tumor is considered to be resectable without evidence of distant metastases (cT1-3 N0-1 M0).
A high percentage of irradical resections is reported in studies using neoadjuvant chemotherapy
followed by surgery versus surgery alone and in trials in which patients are treated with surgery
alone. Improvement of locoregional control by using neoadjuvant chemoradiotherapy might
therefore improve the prognosis in these patients. We previously reported that after neoadjuvant
chemoradiotherapy with weekly administrations of Carboplatin and Paclitaxel combined with
concurrent radiotherapy nearly always a complete R0-resection could be performed. The concept
that this neoadjuvant chemoradiotherapy regimen improves overall survival has, however, to be
proven in a randomized phase III trial.
Methods/design: The CROSS trial is a multicenter, randomized phase III, clinical trial. The study
compares neoadjuvant chemoradiotherapy followed by surgery with surgery alone in patients with
potentially curable esophageal cancer, with inclusion of 175 patients per arm.
The objectives of the CROSS trial are to compare median survival rates and quality of life (before,
during and after treatment), pathological responses, progression free survival, the number of R0
resections, treatment toxicity and costs between patients treated with neoadjuvant
chemoradiotherapy followed by surgery with surgery alone for surgically resectable esophageal
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adenocarcinoma or squamous cell carcinoma. Over a 5 week period concurrent
chemoradiotherapy will be applied on an outpatient basis. Paclitaxel (50 mg/m2) and Carboplatin
(Area-Under-Curve = 2) are administered by i.v. infusion on days 1, 8, 15, 22, and 29. External beam
radiation with a total dose of 41.4 Gy is given in 23 fractions of 1.8 Gy, 5 fractions a week. After
completion of the protocol, patients will be followed up every 3 months for the first year, every 6
months for the second year, and then at the end of each year until 5 years after treatment. Quality
of life questionnaires will be filled out during the first year of follow-up.
Discussion: This study will contribute to the evidence on any benefits of neoadjuvant treatment
in esophageal cancer patients using a promising chemoradiotherapy regimen.
Trial registration: ISRCTN80832026
Background
Esophageal cancer is a highly lethal disease, as reflected by
an overall 5-year survival rate of 10%.[1] With worldwide
almost 400,000 new patients diagnosed annually,
esophageal cancer is the eighth most common cancer, and
sixth on the list of cancer mortality causes.[2] The total
incidence of esophageal cancer is rising, mainly as the
result of a marked rise in the incidence of adenocarci-
noma.[3]
Surgical resection is currently the preferred treatment for
esophageal cancer if a patient is fit enough to undergo
major surgery and the tumor is considered to be resectable
without evidence of distant metastases (cT1-3 N0-1 M0).
However, approximately 30% of operated patients, clini-
cally considered to have resectable disease, have micro-
scopically irradical resections performed on. [4-6]
The goals of neoadjuvant chemotherapy are a reduction of
recurrence from occult lymphatic and/or distant metas-
tases with improvement of survival and possible tumor
shrinkage with an increased radical resectability rate. In
many of the performed phase II studies the patients who
had objective response to chemotherapy had a signifi-
cantly better survival compared to non-responding
patients.[7,8]
The number of randomized phase III studies comparing
neoadjuvant chemotherapy followed by surgery versus
surgery alone is limited. [5-13] The results of these rand-
omized phase III studies and the results of reviews show
that the possible benefit, if any, of neoadjuvant-chemo-
therapy for patients with esophageal cancer is small. It is
uncertain whether such a small potential survival benefit
outweighs the morbidity caused by such a treat-
ment.[14,15] A surgery only arm is therefore still consid-
ered to be appropriate in randomized phase III studies for
patients with esophageal cancer.
Chemotherapy and radiotherapy can interact in several
ways. Both treatment modalities may be active against dif-
ferent tumor cell populations (additive effect), the chem-
otherapy may be effective against micrometastases while
radiation is active locoregionally ("spatial cooperation").
Chemotherapy may synchronize cells in a vulnerable
phase for radiotherapy, decrease repopulation after radio-
therapy and, by shrinking a tumor, enhance reoxygena-
tion, which is advantageous for radiotherapy.[16,17]
In an Intergroup trial (INT 0123 – RTOG 94-05) patients
were randomized to receive the chemoradiotherapy regi-
men as was used in the RTOG 85-01 trial (with 50 Gy radi-
otherapy) or the same chemotherapy regimen combined
with 64.8 Gy radiotherapy.[18,19] After an interim analy-
sis the trial was closed prematurely because of a high
number of treatment related deaths in the high-dose radi-
otherapy arm. There was no significant difference in
median or 2-year survival between the two arms. The
EORTC reported on a prospective randomized study of
split-course radiotherapy (2 × 20 Gy, 4 Gy each fraction, 5
fractions a week with a 2 week gap) with or without 2
courses cisplatin 100 mg/m2 given 3 or 4 days before the
start of radiotherapy and 4 courses afterwards.[20] The
median overall survival was 7.9 months for patients in the
radiotherapy arm en 9.6 months for the patients treated
with chemoradiotherapy. There was no significant differ-
ence in overall survival. Median time to local progression
was 6.2 months against 10.9 months in favor of the chem-
oradiotherapy arm. This split course radiotherapy and
timing of chemotherapy may be not considered optimal
nowadays.
These studies show that concurrent chemoradiation is rec-
ommended compared to radiotherapy alone. Further-
more, higher dose of radiotherapy (50 versus 64 Gy) in
combination with chemotherapy will increase toxicity
rates with no difference in survival.
In most concurrent chemoradiotherapy studies the classic
5-fluorouracil – cisplatin regimen has been used. More
recently, studies with taxanes as concurrently adminis-
tered cytotoxic drugs showed promising results. The com-BMC Surgery 2008, 8:21 http://www.biomedcentral.com/1471-2482/8/21
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bination of Paclitaxel and Carboplatin with concurrent
radiotherapy has been successfully applied in patients
with advanced non-small cell lung cancer. In 3 studies the
combination of Paclitaxel and Carboplatin was given
weekly with concurrent chest radiotherapy followed by 2
21-day cycles of consolidation chemotherapy. [21-23]
These studies reported no unexpected toxicity, and
esophagitis was the most frequent severe toxicity. The
response rates were high and the early survival results
were encouraging. Another approach was two induction
cycles of Paclitaxel and Carboplatin prior to chest radio-
therapy with concurrent chemotherapy of Paclitaxel and
Carboplatin [24,25] or followed by 2 additional chemo-
therapy cycles.[26] These studies reported lower response
rates than the first approach, however, survival was simi-
lar. Awaiting conclusive randomized trials the combina-
tion of Paclitaxel, Carboplatin and radiation is a
promising treatment for locally advanced non-small cell
lung cancer with high response rates and acceptable toxic-
ity.
A few years ago, a phase II study was performed in Rotter-
dam.[27] In this study patients with resectable adenocar-
cinoma or squamous cell carcinoma of the esophagus
were treated with neoadjuvant concurrent chemoradia-
tion. Patients were treated with 5 weekly cycles of Paclit-
axel (50 mg/m2) and Carboplatin (AUC = 2) in
combination with 41.4 Gy radiotherapy given in 23 frac-
tions. Forty patients have completed treatment as per pro-
tocol. All patients received 100% of the planned dose of
chemotherapy and radiotherapy. Myelotoxicity was mild
and no infectious complications were observed. Esophag-
itis was the predominant toxicity and three patients
required tube feeding, however, all these patients had
already a severely impaired passage for food at the start of
treatment. All but one patient had a radical surgical resec-
tion (R0-resection). This compares favorably with the rad-
ical resection rate in other studies with or without
neoadjuvant chemotherapy.[5,6] Many patients had
either a complete pathological response or only small
tumor remnants after completion of the chemoradiation
and all but one had negative lymph nodes.
A high percentage of irradical resections is reported in
studies using surgery alone or neoadjuvant chemotherapy
followed by surgery.[5,6,28] It is thus obvious that ade-
quate locoregional control is still an important issue in
the treatment of patients with esophageal cancer.
Improvement of loco-regional control by using neoadju-
vant chemoradiotherapy might therefore improve the
prognosis in these patients. The results of our phase II
study with neoadjuvant chemoradiotherapy with weekly
administrations of Carboplatin and Paclitaxel combined
with concurrent radiotherapy show that with this regimen
nearly always a complete R0-resection can be per-
formed.[27] The concept that neoadjuvant chemoradio-
therapy improves the overall survival has, however, to be
proven in a randomized phase III trial.
Methods/design
Study objectives
The objective of the CROSS trial is to compare median
survival rates and quality of life (before, during and after
treatment) between patients treated with neoadjuvant
chemoradiotherapy followed by surgery with surgery
alone for surgically resectable esophageal adenocarci-
noma or squamous cell carcinoma.
As secondary objectives we aim to compare pathological
responses, progression free survival, the number of R0
resections, treatment toxicity and costs.
Study design
The CROSS trial is a multicenter, randomized phase III,
clinical trial. The study started on 1 January 2004 and the
duration of inclusion will be approximately 5 years. The
study compares neoadjuvant chemoradiotherapy fol-
lowed by surgery with surgery alone in patients with
potentially curable esophageal cancer, with inclusion of
175 patients per arm.
Patient selection
Patients with histologically proven squamous cell carci-
noma or adenocarcinoma of the esophagus or gastro-
esophageal junction will undergo extensive preoperative
staging, including endosonography and spiral CT-scan of
the chest and abdomen. The tumor must not extend more
than 2 cm into the gastric cardia. Longitudinal tumor
length must not exceed 8 cm, radial size must not exceed
5 cm. cT1N0 tumors are not eligible. Patients must have
adequate hematological, renal, hepatic and pulmonary
functions defined as: granulocytes ≥ 1.5 × 109/L, platelets
≥ 100 × 109/L, total bilirubin ≤ 1.5 × upper normal limit,
creatinine ≤ 120 μmol/L and FEV1 ≥ 1.5 L. In the absence
of local irresectability and/or distant dissemination
patients with an acceptable general condition (ECOG per-
formance status 0, 1, 2; weight loss < 10%) will be invited
to participate in the randomized trial. After written, vol-
untary, informed consent and stratification for tumor
type, treatment center, clinical lymph node status, and
WHO performance status the patients will be randomized
between the two treatment-arms (neoadjuvant chemora-
diation followed by surgery versus surgery alone).
Chemotherapy regimen
Paclitaxel 50 mg/m2 and Carboplatin AUC = 2 will be
given by intravenous infusion on days 1, 8, 15, 22 and 29.
All patients receiving Paclitaxel will receive half an hour
before the start of the Paclitaxel infusion premedication:BMC Surgery 2008, 8:21 http://www.biomedcentral.com/1471-2482/8/21
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Dexamethason 10 mg i.v., Clemastine (Tavegil) 2 mg i.v.
and Ranitidine (Zantac) 50 mg i.v..
At hour 0, the total calculated dose of Paclitaxel, diluted
in 500 ml of normal saline will be infused over one hour.
After the completion of the Paclitaxel infusion, 100 ml
NaCl 0.9% will be infused over 0.5 h, followed by an infu-
sion of 8 mg Ondansetron or its equivalent diluted in 100
ml NaCl 0.9% over 0.5 hour. Hereafter the total calculated
dose of Carboplatin, diluted in 500 ml glucose 5% will be
infused over one hour (doses Carboplatin > 250 mg
should be dissolved in 1000 ml glucose 5%). The absolute
dose of Carboplatin will be calculated for the target AUC
= 2 according to the following formula: the absolute dose
of Carboplatin = [target AUC] × (Glomerular Filtration
Rate + 25).
It is possible that some patients will experience asympto-
matic bradycardia during the Paclitaxel infusion. In addi-
tion, hypersensitivity reactions are possible and generally
occur within the first few minutes of initiating the infu-
sion. For these reasons, it is recommended that there is
constant supervision and that the vital signs are moni-
tored every fifteen minutes during Paclitaxel administra-
tion. Thereafter, patients may be observed and heart rate
and blood pressure checked if necessary, according to clin-
ical symptoms.
Radiotherapy treatment
A total dose of 41.4 Gy will be given in 23 fractions of 1.8
Gy, 5 fractions per week, starting the first day of the first
cycle of chemotherapy. All patients will be radiated by
external beam radiation, using 3-D conformal radiation
technique. The patient will be positioned in supine posi-
tion. Reproducibility will be assessed by orthogonal laser
beams.
The Gross Tumor Volume (GTV) is defined by the primary
tumor and any enlarged regional lymph nodes.[29], and
will be drawn on each relevant CT slice. The GTV will be
determined using all available information (physical
examination, endoscopy, EUS, CT-thorax/abdomen).
The Planning Target Volume (PTV) will provide a proxi-
mal and distal margin of 4 cm, in case of tumor extension
into the stomach, a distal margin of 3 cm will be chosen.
A 2 cm radial margin around the GTV will be provided to
include the area of subclinical involvement around the
GTV and to compensate for tumor motion and set-up var-
iations.
Both lungs will be contoured. The heart will be contoured
on all slices; its cranial border will include the infundibu-
lum of the right ventricle and the apex of both atria.[30],
and will exclude the great vessels as much as possible. The
caudal border will be defined as the lowest part of the left
ventricle's inferior wall that is distinguishable from the
liver. The spinal canal will be contoured and taken to rep-
resent the spinal cord. Prior to the start of the irradiation
a planning CT scan will be made from the cricoid to L1
vertebra with a slice thickness of 5 mm, with the patient
in treatment position. The isocenter will be determined at
the planning-CT.
Radiation therapy will be delivered using a multiple field
technique. Treatment can be given with the combination
of anterior/posterior, oblique or lateral field. Customized
blocks or a multi-leaf collimator will be used to shape the
treatment fields. All patients will undergo a 3D planning.
Beams-eye-view (BEV) displays will be used to ensure
optimal target volume coverage and optimal normal tis-
sue sparing. The most appropriate technical solutions
(e.g. beam quality, field arrangement, conformal therapy
planning) will be chosen as long as they comply with the
International Commission on Radiation Units and Meas-
urements (ICRU) 50/62 safety margins and homogeneity
requirements.
Dose-Volume-Histograms (DVHs) of both lungs, the
heart and spinal cord will be obtained for all patients.
DVHs will mainly be used to document the normal tissue
damage. DVHs may also help to select the most appropri-
ate treatment plan. The volume of lung tissue that receives
20 Gy or more will not exceed 30% of the total lung vol-
ume (V20 Gy lung < 30%). The volume of the heart that
receives 40 Gy will not exceed 30% of the heart volume
(V40 Gy heart < 30%) and the volume of the liver that
receives 30 Gy will not exceed 60% of the total liver vol-
ume (V30Gy liver < 60%). There is no limit for the maxi-
mal length of involved esophagus as long as the normal
tissue criteria are not exceeded.
The risks for severe pneumonitis for patients treated under
this protocol will be minimized as the volume of both
lungs will be limited by the use of BEV planning and field-
shaping (with optimal sparing of both lungs). The spinal
cord tolerance (50 Gy) will not be exceeded with this tech-
nique.
Radiation therapy will be delivered with megavoltage
equipment with photon energies of equal to or greater
than 6 MV. A multileaf collimator or individually shaped
blocks will be used to shape the irradiation portal accord-
ing to the planning target volume.
The prescription dose will be specified at the ICRU 50/62
reference point, which will be the isocenter for most
patients. The daily prescription dose will be 1.8 Gy at the
ICRU reference point and the 95% isodose must encom-
pass the entire planning target volume (PTV). The maxi-BMC Surgery 2008, 8:21 http://www.biomedcentral.com/1471-2482/8/21
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mum to the PTV must not exceed the prescription dose by
> 7% (ICRU 50/62 guidelines). Tissue density inhomoge-
neity correction will be used. Portal images will be
obtained during the first fraction of all fields. On indica-
tion portal images will be repeated.
Chemotherapeutic toxicity
If on day 8, 15, 22, 29, and 36 the WBC are < 1.0 × 109/L
and/or platelets < 50 × 109/L, chemotherapy will be
delayed by 1 week until recovery above these values. In
case of febrile neutropenia (granulo's < 0.5 × 109/L and
fever > 38.5°C) or in case of severe bleeding or requiring
≥ 2 units of platelet transfusions further chemotherapy
will be withheld.
Hypersensitivity reactions will be classified as mild, mod-
erate or severe. Definitions and management guidelines
are outlined in table 1. Other toxic reactions and the pre-
scribed management of these reactions are outlined in
table 2.
Radiation toxicity
Radiotherapy, especially concurrent with chemotherapy
can lead to acute esophagitis. In some cases medical sup-
port and/or a feeding tube will be necessary. In the event
of grade 4 radiation induced esophagitis both chemother-
apy and radiotherapy will be withheld until the esophag-
itis has recovered to grade 3. Other acute complications of
the radiation therapy are erythema, cough, nausea, fatigue
and weight loss. In the first weeks to six months after the
irradiation radiation pneumonitis or fistula formation
can occur.
Surgery
Patients randomized for surgery alone will be treated as
soon as possible after randomization. In the chemoradia-
tion arm, surgery will be performed preferably within 6
weeks after the completion of the chemoradiation. For
carcinomas proximal to the tracheal bifurcation a tran-
sthoracic esophageal resection with a two field lymph
node dissection is preferred. For carcinomas distal of the
tracheal bifurcation but proximal to the gastro-esophageal
junction, a transthoracic approach with a two field lymph
node dissection or a transhiatal approach can be per-
formed, depending on both patient characteristics and
local expertise.[31] For distal tumors involving the gastro-
esophageal junction a transhiatal esophageal resection is
preferred.
A wide local excision including the N1 lymph nodes is car-
ried out in both techniques including a standard excision
of the lymph nodes around the celiac axis (separately col-
lected with left gastric artery marked by a suture). The con-
tinuity of the digestive tract will be restored by a gastric
tube reconstruction or a colonic interposition procedure
with an anastomosis in the neck.
Pathology
The resection specimen will be evaluated essentially using
the standard protocol (margins, tumor type and exten-
sion, lymph nodes). The most recent UICC protocol is
used for TNM-classification and stage grouping.[32,33] In
these resection specimens special attention will be given
to the effects of the neoadjuvant chemoradiation, i.e.
tumor reduction and therapy effects. The effect of the
Table 1: Hypersensitivity reactions after chemotherapy: classification and management
Classification of reactions Management of reactions
One or more mild symptoms: Complete chemotherapy infusion with supervision at bedside. No treatment required.
• mild flushing
￿ rash
￿ pruritis
One or more moderate symptoms: Stop chemotherapy infusion, venous infusion of antihistamine (Clemastine 2 mg IV and 
Dexamethasone 10 mg IV), → after recovery of symptoms resume paclitaxel infusion at a rate 
of 20 ml/h for 15 minutes then 50 ml/h for 15 minutes then, if no further symptoms, at full dose 
rate until infusion is complete.
￿ moderate rash
￿ flushing
￿ mild dyspnea
￿ chest discomfort
￿ mild hypotension
One or more severe symptoms: Stop chemotherapy infusion, give IV antihistamine and steroid as above. Add epinephrine or 
bronchodilators if indicated, report as an adverse event, the patient will go off protocol therapy.
￿ respiratory distress requiring treatment
￿ generalized urticaria
￿ angioedema
￿ hypotension requiring therapyBMC Surgery 2008, 8:21 http://www.biomedcentral.com/1471-2482/8/21
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chemoradiation varies from zero to 100%. In many cases
a multifocal tumor appearance is present with intertwined
therapy effects. In some cases only scattered tumor cells
are visible, often with bizarre morphologies. Therapy
effects include necrosis, inflammation with multinucle-
ated giant cells, fibrosis and calcifications. In general
fibrosis is the most remarkable effect, and it can be used
to judge the extension of the untreated tumor. The Man-
dard score is used to quantify the anti-tumor effect.[34]
The lymph node dissection should contain at least 10
nodes derived from both regional (mediastinal, esopha-
geal) and distant sites (celiac region).
The pathology report should contain the following: site of
the tumor/lesion, type and grade of the tumor, extension
into the esphageal wall, resection margins, therapy effects
(Mandard score), lymph node status including the site
and the number of nodes with therapy effects.
Follow-up
After completion of the protocol, patients will be fol-
lowed up every 3 months for the first year, every 6 months
for the second year, and then at the end of each year until
5 years after treatment, to document late toxic effects and,
if applicable, disease relapse or progression, and death.
Patients in the chemoradiation arm will be asked to fill
out quality of life questionnaires before and after therapy
and every three months during the first year of follow up.
Patients randomized for surgery alone will fill out the
questionnaires before surgery and every three months
during the first year of follow-up.
Statistical analysis
Data will be analyzed according to the 'Intention to treat'
principle. We believe that an estimated difference in
median survival of 16 months (surgery alone arm) versus
22 months (multimodality treatment arm) would justify
applying this regimen in the future. We calculated that for
this purpose 350 patients, 175 patients per arm, have to
be enrolled. We assumed a two-sided significance level of
0.05 and a power of 0.80.[35] Survival will be dated from
the date of randomization to death. Estimates of median
overall survival will be based on the Kaplan-Meier
method and log-rank tests will be used to determine sig-
nificance. Cox regression analyses will be conducted to
identify prognostic factors for survival benefit, which will
be used in adjusted analyses of the treatment effect.
Ethical considerations
The responsible physician will inform the patient about
the background and present knowledge on the drugs
under study with special reference to known activity and
toxicity. It must be emphasized that the patient is allowed
to refuse the treatment either before or at any time during
the study. Before the patient is entered in the study the
patient's written consent will be obtained. The principal
investigator (AvdG) will ensure that this study will be car-
ried out in agreement with the "Declaration of Helsinki,
Table 2: toxic reactions and prescribed management
Reaction Management of reactions
Renal:
Creatinin ≤ 1.5 × upper limit of normal at day of treatment Continue treatment
Creatinin > 1.5 × upper limit of normal Establish intravenous infusion the evening preciding treatment at a rate 
to correct any volume deficits and produce a urine flow ≥ ml/h. Repeat 
serum creatinin value in the morning:
≤ 1.5 × upper limit of normal → proceed treatment
> 1.5 × upper limit of normal → stop chemotherapy
Gastrointestinal:
Mucositis with oral ulcers or protracted vomiting despite antiemetic 
premedication
Delay chemotherapy one week
Neurologic:
CTC grade ≤ 2 Continue therapy
CTC grade > 2 Stop chemotherapy
Cardiac:
Asympotomatic bradycardia or isolated asymptomatic ventricular 
extrasystoles
Continue therapy under continuous cardiac monitoring
First degree AV block Continue therapy under continuous cardiac monitoring
Symptomatic arrhythmia or AV block (except 1st degree) or other 
heart blocks
Stop chemotherapy, manage arrhythmia according to standard practice; 
patient goes off protocol
CTC Common Toxicity CriteriaBMC Surgery 2008, 8:21 http://www.biomedcentral.com/1471-2482/8/21
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Tokyo, Venice" or the laws and regulation of the country,
whichever provides greater protection of the individual.
The study has been approved by the institutional ethical
review committee.
Adverse events
Any unexpected clinical adverse event or abnormal labo-
ratory test value that is serious, including death or over-
dose, occurring during the course of the study, irrespective
of the treatment received by the patient, must be reported
to the study coordinator within one working day of occur-
rence.
An adverse event is serious if it is fatal or life threatening,
permanently disabling, requiring hospitalization other
than for planned treatment or if it is an overdose. A death
occurring during treatment within 4 weeks after stopping
treatment, whether treatment-related or not must be
reported to the study coordinator.
Discussion
A number of phase III trials have been performed compar-
ing chemoradiotherapy followed by surgery versus surgery
alone.[11,36-44] Only two trials showed significant ben-
efit for use of neoadjuvant chemoradiotherapy, of which
the Walsh study has been heavily criticized mainly
because of poor outcome of patients treated with surgery
alone, and the CALGB 9781 study because of accrual of
only 56 of the 500 patients who were initially intended to
be included.[41,44] In the 8 other trials no benefit for the
chemoradiotherapy arm could be demonstrated.[36-
40,42,43]
Several meta-analyses have been performed over the
years, with varying conclusions.[15,45-49] The most
recent meta-analysis from Gebski et al. reported a 13%
absolute difference in survival at 2 years in favor of those
patients receiving neoadjuvant chemoradiotherapy.[46]
However, it can not be overemphasized that all these
meta-analyses were based on studies with small sample
sizes and that staging techniques, surgical quality and
quality of chemoradiotherapy were frequently not meet-
ing today's standard. Furthermore, a considerable hetero-
geneity is present between the populations of the various
trials and there was an overrepresentation of patients with
squamous cell carcinomas. In addition, studies using both
sequential chemoradiotherapy and concurrent chemora-
diotherapy were included in this meta-analysis. Finally,
no correction for the extra time that chemoradiotherapy
brings along for patients was made in any of the trials or
meta-analyses. For instance, if chemoradiation yields a
survival benefit of a few months and it also costs a few
months of extra time for recovery compared with surgery
alone, the benefit would be completely lost. Recapitulat-
ing, conclusions of even well performed meta-analyses
based on poorly designed primary studies remain ques-
tionable.
Currently most patients in Europe and the US diagnosed
with esophageal cancer present with adenocarcinomas
located in the distal esophagus. Many of these patients are
nowadays routinely treated with neoadjuvant chemoradi-
otherapy. Unfortunately, this policy is based on data of
less than 200 patients with an adenocarcinoma of the
esophagus treated with concurrent neoadjuvant chemora-
diotherapy, as shown by the latest meta-analysis. There-
fore, we believe surgery alone is still an acceptable
treatment for patients with resectable esophageal cancer.
Based on the favorable results of our phase II trial with a
neoadjuvant chemoradiotherapy regimen consisting of
weekly administrations of Carboplatin and Paclitaxel
combined with concurrent radiotherapy we initiated a
phase III trial comparing this regimen with surgery alone
in a sufficiently large group of patients. The accrual of this
trial, a total of 350 randomized patients, is expected to be
completed in the last quarter of 2008. This study will con-
tribute to the evidence on any benefits of neoadjuvant
treatment in esophageal cancer patients using a promising
chemoradiotherapy regimen.
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